Ⅳ期维吾尔族NSCLC患者EML4-ALK、EGFR基因突变状态及生存分析  

EML4-ALK and EGFR mutation status and survival analysis in Uygur with stage Ⅳ NSCLC

作　　者：王强[1] 张峤[1] 曹燕珍[2] 陶洁[1] 单莉[1] 

机构地区：[1]新疆医科大学附属肿瘤医院肺内科一病区,830011 [2]新疆医科大学附属肿瘤医院病理科,830011

出　　处：《天津医药》2016年第2期200-204,共5页Tianjin Medical Journal

基　　金：吴阶平医学基金会临床科研专项资助(320.6799.1130)

摘　　要：目的探讨棘皮动物微管样蛋白4-间变淋巴瘤激酶(EML4-ALK)和表皮生长因子受体(EGFR)基因突变状态与未经系统酪氨酸激酶抑制剂(TKIs)治疗的Ⅳ期维吾尔族非小细胞肺癌(NSCLC)患者长期生存的关系。方法收集97例未经TKIs治疗的Ⅳ期维吾尔族NSCLC患者的组织标本,分别运用FISH及ARMS方法检测EML4-ALK基因融合及EGFR基因突变状态并进行生存分析。结果 97例Ⅳ期维吾尔族NSCLC组织中,6例(6.2%)存在EML4-ALK基因融合,26例(26.8%)存在EGFR基因突变。生存分析显示,EML4-ALK基因融合患者与EML4-ALK基因未融合患者总生存期(OS)差异无统计学意义(P=0.941),EGFR基因突变患者与EGFR野生型患者OS比较差异无统计学意义(P=0.607)。EGFR/EML4-ALK综合突变对Ⅳ期维吾尔族NSCLC患者长期生存发现,EGFR突变型组、EML4-ALK阳性组、EML4-ALK阴性+EGFR野生型组患者中位OS分别为17.7、17.3、16.2个月,差异无统计学意义(P=0.915)。结论在排除TKIs治疗影响的情况下,EML4-ALK融合基因与EGFR基因突变状态尚不能作为评估Ⅳ期维吾尔族NSCLC患者预后的独立因素。Objective To investigate the relationship between the echinoderm microtubule associated protein like 4- anaplastic lymphoma kinase （EML4-ALK） and epithelial growth factor receptor （EGFR） mutation status and overall survivaI （OS） in Uygur patients with stage 1V non-small cell lung cancer （NSCLC） who did not accept tyrosine kinase inhibitor treat- ment. Methods Totally 97 tissue samples were collected from Uygur patients with stage IV NSCLC who did not accept tyrosine kinase inhibitor treatment. EML4-ALK fusion gene and EGFR mutation status were detected by using FISH and ARMS methods. The survival rates were analysed. Results In 97 tissue samples, EMIA-ALK fusion genes were found in 6 （6.2%） samples, EGFR mutations were found in 26 （26.8%） samples. The survival analysis showed that there was no significant difference in OS between EML4-ALK fusion gene group and no EML4-ALK fusion gene group （P=0.941）. There was no signifi- cant difference in OS between EGFR mutation group and wild-type EGFR group （P=0.607）. The values of median OS were 17.7 months, 17.3 months and 16.2 months for EGFR mutant group, EML4-ALK positive group and EML4-ALK negative＋ EGFR wild-type group, and thre was no significant difference between them （P=0.915）. Conclusion Excluding the therapeutic influence in TKIs, EML4-ALK fusion gene and EGFR mutation status of tumor tissue can not be used as an independent factor in assessing the prognosis in Uygur patients with stage IV NSCLC.

关 键 词：癌 非小细胞肺 受体 表皮生长因子 突变 维吾尔族 非小细胞肺癌 棘皮动物微管样蛋白4-间变淋巴瘤激酶 生存分析 

分 类 号：R734.2[医药卫生—肿瘤]